A cohort comprising AD patients (n = 102), aMCI patients (n = 65), and age- and sex-matched cognitively normal (CN) controls (n = 93) was assembled to assess urinary CX3CL1 level variations across the groups (Table 1). This evidence concerns the gene CX3CL1 and Alzheimer disease.